Global Cold Sore Treatment For Hsv 1 Virus Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2024 –2031 |
 Tamanho do mercado (ano base ) | USD 927.29 Million |
 Tamanho do mercado ( Ano de previsão) | USD 1,501.88 Million |
 CAGR |
% |
| Principais participantes do mercado |
>Mercado global de tratamento do herpes labial (para vírus HSV 1), por tipo de tratamento (medicamentos, produtos aplicados, adesivos para herpes labial e outros (produtos não medicamentosos)), via de administração (oral, tópico e outros), modo de compra ( Medicamento de venda livre e prescrito), tipo de estirpe (vírus herpes simplex tipo 1 e vírus herpes simplex tipo 2), tipo de medicamento (genérico e de marca), tipo de população (adultos, pediatria e geriatria), género ( feminino e masculino), Utilizador Final (Saúde Domiciliária, Hospitais, Clínicas Especializadas e Outros), Canal de Distribuição (Concursos Directos, Venda a Retalho e Outros) - Tendências do Sector e Previsão para 2031.
Tratamento do herpes labial (para vírus HSV 1) Análise de mercado e tamanho
Espera-se que o mercado global de tratamento do herpes labial (para o vírus HSV 1) ganhe crescimento de mercado no período de previsão de 2024 a 2031.
O mercado global de tratamento do herpes labial (para o vírus HSV 1) é impulsionado pela elevada prevalência dos vírus HSV-1 e H11 e é um dos principais impulsionadores do mercado global de tratamento do herpes labial (para o vírus HSV 1). O HSV-1 está generalizado, infetando cerca de 67% da população mundial com menos de 50 anos de idade. Da mesma forma, as infecções por H11 são comuns entre as aves de capoeira, com transmissão ocasional para o Homem.
Esta prevalência impulsiona a procura por tratamentos eficazes. As pessoas com HSV-1 ou H11 apresentam frequentemente surtos recorrentes de herpes labial, que podem ser dolorosos e desagradáveis. Isto cria uma forte procura por parte dos consumidores por tratamentos que possam aliviar os sintomas, reduzir a frequência dos surtos e prevenir a transmissão. As mudanças no estilo de vida, incluindo o aumento do stress, a fadiga e a exposição ao sol, podem desencadear surtos. A população idosa é também mais suscetível ao herpes labial, contribuindo para taxas de infeção mais elevadas.
A Data Bridge Market Research analisa que o mercado global de tratamento do herpes labial (para o vírus HSV 1) está a crescer com um CAGR de 6,6% no período de previsão de 2024 a 2031 e deverá atingir os 1.501,88 milhões de dólares até 2031, de 927,29 milhões de dólares em 2023. .
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2024 a 2031 |
|
Ano base |
2023 |
|
Anos históricos |
2022 (personalizável 2016-2021) |
|
Unidades Quantitativas |
Receita em milhões de dólares |
|
Segmentos cobertos |
Tipo de tratamento (medicamentos, produtos aplicados, adesivos para herpes labial e outros (produtos não medicamentosos)), via de administração (oral, tópico e outros), modo de compra ( medicamento de venda livre e prescrito ), tipo de estirpe (Herpes Simplex Vírus tipo 1 e vírus herpes simplex tipo 2), tipo de medicamento (genérico e de marca), tipo de população (adultos, pediatria e geriatria), género (feminino e masculino), utilizador final ( saúde domiciliária , hospitais, clínicas especializadas e outros). ), Canal de Distribuição (Licitações Diretas, Vendas a Retalho e Outros) |
|
Países abrangidos |
EUA, Canadá e México, Reino Unido, Alemanha, França, Espanha, Itália, Bélgica, Rússia, Suíça, Holanda, Turquia e resto da Europa, China, Austrália, Japão, Índia, Singapura, Coreia do Sul, Malásia, Tailândia, Indonésia , Filipinas e restante Ásia-Pacífico, Brasil, Argentina e restante América do Sul, África do Sul, Egito, Arábia Saudita, Emirados Árabes Unidos e restante Médio Oriente e África |
|
Participantes do mercado abrangidos |
KGaA, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Quantum Health, GSK plc., Haleon Group of Companies, Church & Dwight Co., Inc., Hikma Pharmaceuticals PLC, Viatris Inc ., Carma Labs Inc., URGO MEDICAL, Apotex Inc., Amneal Pharmaceuticals LLC, Blistex Inc., FOCUS CONSUMER HEALTHCARE, Hetero Healthcare Limited, Amparo medical Technologies e Devirex AG entre outros |
Definição de mercado
O HSV-1, ou vírus herpes simplex tipo 1, é um vírus comum que causa herpes labial, também conhecido como bolhas de febre, nos lábios e à volta da boca. Estas feridas são bolhas cheias de líquido que podem ser dolorosas e durar cerca de 7 a 10 dias.
O tratamento para o herpes labial envolve geralmente medicamentos antivirais, como o aciclovir, famciclovir ou valaciclovir, que podem ajudar a reduzir a gravidade e a duração dos surtos. Os cremes e pomadas de venda livre, como os que contêm docosanol ou álcool benzílico , também podem proporcionar alívio dos sintomas. Manter a área afetada limpa e evitar fatores desencadeantes, como o stress ou a exposição solar, pode ajudar a prevenir os surtos.
Dinâmica do mercado global do tratamento do herpes labial (para vírus HSV 1)
Esta secção trata da compreensão dos impulsionadores do mercado, vantagens, oportunidades, restrições e desafios. Tudo isto é discutido em detalhe abaixo:
Motoristas
- Crescente prevalência de infecção por herpes labial
A crescente prevalência de infeções por herpes labial, impulsionada pela mudança do estilo de vida, pelo envelhecimento da população, pelo aumento da consciencialização e pela globalização, é um fator-chave do mercado global de tratamento do herpes labial (para o vírus HSV 1) . Prevê-se que esta tendência se mantenha, levando a uma maior inovação e ao desenvolvimento de novas opções de tratamento para os indivíduos afectados por estas infecções.
- Crescente sensibilização sobre os sintomas de herpes labial e opções de tratamento
A maior acessibilidade da informação sobre o herpes labial através de vários canais de media, como a internet, as redes sociais e as campanhas de saúde, aumentou a consciencialização sobre os sinais e sintomas do herpes labial. Esta maior consciencialização resultou em mais indivíduos a procurar aconselhamento médico e tratamento para o seu herpes labial, o que, por sua vez, impulsionou o crescimento do mercado.
Oportunidade
- Avanços crescentes nos tratamentos para as infeções por herpes labial
Breakthroughs in the treatment of cold sores (HSV-1) and herpes zoster (varicella-zoster virus) infections have led to the development of more potent antiviral medications with fewer side effects. Innovative drug delivery systems, such as liposomal formulations, have enhanced treatment efficacy and patient compliance.
Restraint/Challenge
- Increasing Complexity of Vaccine Development
Developing a vaccine to treat cold sores caused by the HSV-1 virus is met with considerable obstacles. One such challenge is the virus's ability to establish latency in nerve ganglia, making it difficult to target with vaccines as it remains dormant in inactive viral reservoirs. In addition, HSV-1's immune evasion mechanisms pose difficulties in inducing a robust and enduring immune response through vaccination. Despite these challenges, continued research and innovation are crucial to advancing vaccine development and reducing the burden of HSV-1 infections worldwide.
Recent Developments
- In August 2019, Sun Pharmaceutical Industries Ltd. reported that one of its subsidiaries has conceded a license agreement to a subsidiary of China medical system holding ltd. to develop and commercialize 7 generics drugs in China. This agreement helps the company to expand its business and make the product profile strong
- In November 2020, Amneal Pharmaceuticals LLC had declared the FDA approval of its Abbreviated New Drug Application (ANDA) for Acyclovir Cream, 5%. It is the generic version of Zovirax for treatment of herpes labialis in adolescents. The initiative by the company would result in increased distribution of the product, rise in brand recognition and rise in sales. This would result in positive growth of the market
- In August 2020, GSK completes acquisition of Affinivax, Inc. announced that it completed acquisition Cambridge, Massachusetts-based Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical business. Next-generation pneumococcal vaccines are the most developed of a new class of vaccines that Affinivax lead the development of next-generation pneumococcal vaccines
Global Cold Sore Treatment (for HSV 1 Virus) Market Scope
Global cold sore treatment (for HSV 1 virus) market is segmented into nine notable segments based on treatment type, route of administration, mode of purchase, strain type, drug type, population type, gender, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Treatment Type
- Medications
- Applied Products
- Cold Sore Patches
- Others(Non Medicated Products)
On the basis of treatment type, the global cold sore treatment (for HSV 1 virus) market is segmented into medications, applied products, cold sore patches, and others (non medicated products).
Route of Administration
- Oral
- Topical
- Others
On the basis of route of administration, the global cold sore treatment (for HSV 1 virus) market is segmented into oral, topical, and others.
Mode of Purchase
- Over The Counter
- Prescription Drug
On the basis of mode of purchase, the global cold sore treatment (for HSV 1 virus) market is segmented over the counter and prescription drug.
Strain Type
- Herpes Simplex Type 1 Virus
- Herpes Simplex Type 2 Virus
On the basis of strain type, the global cold sore treatment (for HSV 1 virus) market is segmented into herpes simplex type 1 virus and herpes simplex type 2 virus.
Drug Type
- Generic
- Branded
On the basis of drug type, the global cold sore treatment (for HSV 1 virus) market is segmented into generic and branded.
Population Type
- Adults
- Pediatrics
- Geriatrics
On the basis of population type, the global cold sore treatment (for HSV 1 virus) market is segmented into adults, pediatrics, and geriatrics.
Gender
- Female
- Male
On the basis of gender, the global cold sore treatment (for HSV 1 virus) market is segmented into female and male.
End User
- Home healthcare
- Hospitals
- Specialty clinics
- Others
On the basis of end user, the global cold sore treatment (for HSV 1 virus) market is segmented into home healthcare, hospitals, specialty clinics, and others.
Distribution Channel
- Direct Tenders
- Retail sales
- Others
On the basis of distribution channel, the global cold sore treatment (for HSV 1 virus) market is segmented into direct tenders, retail sales, and others.
Global Cold Sore Treatment (for HSV 1 Virus) Market Regional Analysis/Insights
Global cold sore treatment (for HSV 1 virus) market is analyzed, and market size insights and trends are provided by based on treatment type, route of administration, mode of purchase, strain type, drug type, population type, gender, end user, and distribution channel as referenced above.
The countries covered in this global cold sore treatment (for HSV 1 virus) market report are U.S., Canada, and Mexico, U.K., Germany, France, Spain, Italy, Belgium, Russia, Switzerland, Netherlands, Turkey, and rest of Europe, China, Australia, Japan, India, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, and rest of Asia-Pacific, Brazil, Argentina, and rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., and rest of Middle East and Africa.
North America is expected to dominate the global cold sore treatment (for HSV 1 virus) market due to factors like high prevalence of cold sores, advanced healthcare infrastructure, strong consumer awareness and purchasing power, ongoing research and development initiatives, established marketing and distribution networks, and reduced stigma surrounding treatment-seeking behaviors.
U.S. is expected to dominate in the North America cold sore treatment (for HSV 1 virus) market due to factors such as large population, high healthcare expenditure, sophisticated healthcare system, extensive pharmaceutical industry, and widespread consumer awareness and access to cold sore treatments.
Espera-se que a Alemanha domine o mercado europeu de tratamento do herpes labial (para o vírus HSV 1) devido à sua infraestrutura de saúde avançada, à procura significativa dos consumidores por tratamentos para o herpes labial, à forte indústria farmacêutica, aos extensos esforços de investigação e desenvolvimento e redes de distribuição bem estabelecidas, tornando-o um centro de inovação e acessibilidade no tratamento do herpes labial.
Espera-se que a China domine o mercado de tratamento do herpes labial da Ásia-Pacífico (para o vírus HSV 1) devido à sua grande população, aumentando os gastos com a saúde, expandindo a indústria farmacêutica, aumentando a sensibilização dos consumidores e a procura por tratamentos de herpes labial, juntamente com um sistema de saúde em desenvolvimento infraestrutura e uma prevalência crescente de herpes labial.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.
Cenário competitivo e tratamento global do herpes labial (para vírus HSV 1) Análise da quota de mercado
O panorama competitivo do mercado global de tratamento do herpes labial (para o vírus HSV 1) fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, e domínio da aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas no mercado global de tratamento do herpes labial (para o vírus HSV 1).
Alguns dos principais players que operam no mercado global de tratamento do herpes labial (para o vírus HSV 1) são a Fresenius SE & Co. KGaA, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Quantum Health , GSK plc., Haleon Group of Companies, Church & Dwight Co., Inc., Hikma Pharmaceuticals PLC, Viatris Inc., Carma Labs Inc., URGO MEDICAL, Apotex Inc., Amneal Pharmaceuticals LLC, Blistex Inc., FOCUS CONSUMER HEALTHCARE , Hetero Healthcare Limited, Amparo Medical Technologies e Devirex AG, entre outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: REGULATIONS
5.1 REGULATION IN U.S.:
5.2 REGULATION IN CANADA:
5.3 REGULATION IN SPAIN:
5.4 REGULATION IN U.K.:
5.5 REGULATION IN INDIA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING PREVALENCE OF COLD SORE INFECTION
6.1.2 GROWING AWARENESS ABOUT COLD SORE SYMPTOMS AND TREATMENT OPTIONS
6.1.3 IMPACT OF GENERIC DRUGS ON THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET
6.2 RESTRAINTS
6.2.1 DEVELOPMENT OF DRUG-RESISTANT STRAINS OF HSV-1 AND H11 VIRUSES
6.2.2 LACK OF CURATIVE TREATMENT FOR INFECTION
6.3 OPPORTUNITIES
6.3.1 RISING ADVANCEMENTS IN TREATMENTS FOR COLD SORE INFECTIONS
6.3.2 INCREASING ADOPTION OF TELEMEDICINE AND DIGITAL HEALTH SOLUTIONS
6.4 CHALLENGES
6.4.1 INCREASING COMPLEXITY OF VACCINE DEVELOPMENT
6.4.2 SIDE EFFECTS ASSOCIATED WITH MEDICATIONS IN TREATING COLD SORE
7 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 MEDICATIONS
7.2.1 ANTIVIRAL AGENTS
7.2.2 ANALGESIC AGENTS
7.2.3 OTHERS
7.3 APPLIED PRODUCTS
7.3.1 BRANDED
7.3.2 GENERICS
7.4 COLD SORE PATCHES
7.4.1 SEMI OCCLUSIVE HYDROCOLLOID PATCH
7.4.2 FILM FORMING PATCH
7.5 OTHERS (NON MEDICATED PRODUCTS)
8 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ORAL
8.2.1 TABLETS
8.2.2 CAPSULES
8.2.3 OTHERS
8.3 TOPICAL
8.3.1 CREAM
8.3.2 LIP BALM
8.3.3 OTHERS
8.4 OTHERS
9 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE
9.1 OVERVIEW
9.2 OVER THE COUNTER
9.3 PRESCRIPTION DRUG
10 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY STRAIN TYPE
10.1 OVERVIEW
10.2 HERPES SIMPLEX TYPE 1 VIRUS
10.3 HERPES SIMPLEX TYPE 2 VIRUS
11 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DRUG TYPE
11.1 OVERVIEW
11.2 GENERIC
11.3 BRANDED
12 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY POPULATION TYPE
12.1 OVERVIEW
12.2 ADULTS
12.3 PEDIATRICS
12.4 GERIATRICS
13 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY GENDER
13.1 OVERVIEW
13.2 FEMALE
13.3 MALE
14 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY END USER
14.1 OVERVIEW
14.2 HOME HEALTHCARE
14.3 HOSPITALS
14.4 SPECIALTY CLINICS
14.5 OTHERS
15 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDERS
15.3 RETAIL SALES
16 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION
16.1 OVERVIEW
16.2 NORTH AMERICA
16.2.1 U.S.
16.2.2 CANADA
16.2.3 MEXICO
16.3 EUROPE
16.3.1 GERMANY
16.3.2 FRANCE
16.3.3 U.K.
16.3.4 ITALY
16.3.5 SPAIN
16.3.6 RUSSIA
16.3.7 SWITZERLAND
16.3.8 NETHERLAND
16.3.9 TURKEY
16.3.10 BELGIUM
16.3.11 REST OF EUROPE
16.4 ASIA-PACIFIC
16.4.1 CHINA
16.4.2 JAPAN
16.4.3 INDIA
16.4.4 AUSTRALIA
16.4.5 SOUTH KOREA
16.4.6 SINGAPORE
16.4.7 MALAYSIA
16.4.8 PHILIPPINES
16.4.9 INDONESIA
16.4.10 THAILAND
16.4.11 REST OF ASIA-PACIFIC
16.5 SOUTH AMERICA
16.5.1 BRAZIL
16.5.2 ARGENTINA
16.5.3 REST OF SOUTH AMERICA
16.6 MIDDLE EAST AND AFRICA
16.6.1 SOUTH AFRICA
16.6.2 EGYPT
16.6.3 SAUDI ARABIA
16.6.4 U.A.E.
17 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 FRESENIUS SE & CO. KGAA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 ZYDUS PHARMACEUTICALS INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 COMPANY SHARE ANALYSIS
19.2.3 PRODUCT PORTFOLIO
19.2.4 RECENT DEVELOPMENT
19.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 NOVARTIS AG
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 SUN PHARMACEUTICALS INDUSTRIES LIMITED
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 AMNEAL PHARMACEUTICALS LLC
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 AMPARO MEDICAL TECHNOLOGIES
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 APOTEX INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 BLISTEX INC.
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 CARMA LABS INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 CHURCH & DWIGHT CO., INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 DEVIREX AG
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 FOCUS CONSUMER HEALTHCARE
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 GSK PLC.
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENT
19.15 HALEON GROUP OF COMPANIES
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 HETERO HEALTH CARE LIMITED
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 HIKMA PHARMACEUTICALS PLC
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENT
19.18 QUANTUM HEALTH
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENT
19.19 URGO MEDICAL
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENT
19.2 VIATRIS INC.
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tabela
TABLE 1 TREATMENT OF PEDIATRIC HSV INFECTIONS
TABLE 2 TREATMENT OPTIONS
TABLE 3 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 4 GLOBAL MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 GLOBAL MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 6 GLOBAL ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 7 GLOBAL ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 8 GLOBAL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 9 GLOBAL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 10 GLOBAL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 11 GLOBAL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 12 GLOBAL COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 GLOBAL COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 14 GLOBAL OTHERS (NON MEDICATED PRODUCTS) IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 15 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 16 GLOBAL ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 17 GLOBAL ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 18 GLOBAL TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 GLOBAL TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 20 GLOBAL OTHERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 22 GLOBAL OVER THE COUNTER IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 GLOBAL PRESCRIPTION IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY STRAIN TYPE, 2022- 2031 (USD THOUSAND)
TABLE 25 GLOBAL HERPES SIMPLEX TYPE 1 VIRUS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 26 GLOBAL HERPES SIMPLEX TYPE 2 VIRUS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 27 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DRUG TYPE, 2022- 2031 (USD THOUSAND)
TABLE 28 GLOBAL GENERIC IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 29 GLOBAL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 30 GLOBAL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031
TABLE 31 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY POPULATION TYPE, 2022- 2031 (USD THOUSAND)
TABLE 32 GLOBAL ADULTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 33 GLOBAL PEDIATRICS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 34 GLOBAL GERIATRICS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 35 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY GENDER, 2022- 2031 (USD THOUSAND)
TABLE 36 GLOBAL FEMALE IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 37 GLOBAL MALE IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 38 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY END USER, 2022- 2031 (USD THOUSAND)
TABLE 39 GLOBAL HOME HEALTHCARE IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 40 GLOBAL HOSPITALS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 41 GLOBAL SPECIALTY CLINICS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 42 GLOBAL OTHERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 43 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022- 2031 (USD THOUSAND)
TABLE 44 GLOBAL DIRECT TENDERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 45 GLOBAL RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 46 GLOBAL RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031
TABLE 47 GLOBAL OTHERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031
TABLE 48 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 NORTH AMERICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 NORTH AMERICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 53 NORTH AMERICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 NORTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 55 NORTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 56 NORTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 57 NORTH AMERICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 59 NORTH AMERICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 60 NORTH AMERICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 61 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 62 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 64 NORTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 66 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 67 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 68 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 69 NORTH AMERICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 71 U.S. MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 72 U.S. ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 73 U.S. ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 74 U.S. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 U.S. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 U.S. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 77 U.S. COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 78 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 79 U.S. ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 80 U.S. TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 81 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 82 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 83 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 U.S. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 86 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 87 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 88 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 89 U.S. RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 91 CANADA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 CANADA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 CANADA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 CANADA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 95 CANADA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 CANADA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 97 CANADA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 98 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 99 CANADA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 100 CANADA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 101 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 102 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 103 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 104 CANADA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 106 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 107 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 108 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 109 CANADA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 MEXICO MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 112 MEXICO ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 MEXICO ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 114 MEXICO APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 115 MEXICO BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 116 MEXICO APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 117 MEXICO COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 119 MEXICO ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 120 MEXICO TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 121 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 122 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 123 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 MEXICO BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 125 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 126 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 127 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 128 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 129 MEXICO RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 131 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 132 EUROPE MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 EUROPE ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 134 EUROPE ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 EUROPE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 136 EUROPE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 EUROPE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 138 EUROPE COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 139 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 140 EUROPE ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 141 EUROPE TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 142 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 143 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 144 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 145 EUROPE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 146 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 147 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 148 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 149 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 150 EUROPE RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 151 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 152 GERMANY MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 GERMANY ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 GERMANY ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 155 GERMANY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 156 GERMANY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 157 GERMANY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 158 GERMANY COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 159 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 160 GERMANY ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 161 GERMANY TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 162 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 163 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 164 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 165 GERMANY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 167 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 168 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 169 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 170 GERMANY RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 171 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 172 FRANCE MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 173 FRANCE ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 174 FRANCE ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 175 FRANCE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 176 FRANCE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 177 FRANCE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 178 FRANCE COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 179 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 180 FRANCE ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 181 FRANCE TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 182 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 183 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 184 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 185 FRANCE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 186 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 187 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 188 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 189 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 190 FRANCE RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 191 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 192 U.K. MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 193 U.K. ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 194 U.K. ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 195 U.K. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 196 U.K. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 197 U.K. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 198 U.K. COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 199 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 200 U.K. ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 201 U.K. TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 202 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 203 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 204 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 U.K. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 206 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 207 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 208 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 209 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 210 U.K. RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 211 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 212 ITALY MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 213 ITALY ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 214 ITALY ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 215 ITALY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 216 ITALY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 217 ITALY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 218 ITALY COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 220 ITALY ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 221 ITALY TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 222 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 223 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 224 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 225 ITALY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 226 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 227 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 228 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 229 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 230 ITALY RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 231 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 232 SPAIN MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 SPAIN ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 234 SPAIN ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 235 SPAIN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 236 SPAIN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 237 SPAIN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 238 SPAIN COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 239 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 240 SPAIN ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 241 SPAIN TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 242 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 243 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 244 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 245 SPAIN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 246 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 247 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 248 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 249 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 250 SPAIN RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 251 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 252 RUSSIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 253 RUSSIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 254 RUSSIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 255 RUSSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 256 RUSSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 257 RUSSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 258 RUSSIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 259 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 260 RUSSIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 261 RUSSIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 262 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 263 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 264 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 265 RUSSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 266 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 267 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 268 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 269 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 270 RUSSIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 271 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 272 SWITZERLAND MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 273 SWITZERLAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 274 SWITZERLAND ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 275 SWITZERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 276 SWITZERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 277 SWITZERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 278 SWITZERLAND COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 279 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 280 SWITZERLAND ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 281 SWITZERLAND TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 282 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 283 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 284 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 285 SWITZERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 286 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 287 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 288 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 289 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 290 SWITZERLAND RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 291 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 292 NETHERLAND MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 293 NETHERLAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 294 NETHERLAND ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 295 NETHERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 296 NETHERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 297 NETHERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 298 NETHERLAND COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 299 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 300 NETHERLAND ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 301 NETHERLAND TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 302 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 303 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 304 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 305 NETHERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 306 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 307 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 308 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 309 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 310 NETHERLAND RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 311 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 312 TURKEY MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 313 TURKEY ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 314 TURKEY ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 315 TURKEY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 316 TURKEY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 317 TURKEY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 318 TURKEY COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 319 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 320 TURKEY ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 321 TURKEY TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 322 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 323 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 324 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 325 TURKEY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 326 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 327 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 328 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 329 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 330 TURKEY RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 331 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 332 BELGIUM MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 333 BELGIUM ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 334 BELGIUM ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 335 BELGIUM APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 336 BELGIUM BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 337 BELGIUM APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 338 BELGIUM COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 339 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 340 BELGIUM ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 341 BELGIUM TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 342 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 343 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 344 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 345 BELGIUM BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 346 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 347 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 348 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 349 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 350 BELGIUM RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 351 REST OF EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 352 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 353 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 354 ASIA-PACIFIC MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 355 ASIA-PACIFIC ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 356 ASIA-PACIFIC ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 357 ASIA-PACIFIC APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 358 ASIA-PACIFIC BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 359 ASIA-PACIFIC APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 360 ASIA-PACIFIC COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 361 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 362 ASIA-PACIFIC ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 363 ASIA-PACIFIC TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 364 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 365 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 366 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 367 ASIA-PACIFIC BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 368 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 369 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 370 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 371 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 372 ASIA-PACIFIC RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 373 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 374 CHINA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 375 CHINA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 376 CHINA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 377 CHINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 378 CHINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 379 CHINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 380 CHINA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 381 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 382 CHINA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 383 CHINA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 384 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 385 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 386 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 387 CHINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 388 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 389 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 390 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 391 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 392 CHINA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 393 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 394 JAPAN MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 395 JAPAN ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 396 JAPAN ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 397 JAPAN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 398 JAPAN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 399 JAPAN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 400 JAPAN COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 401 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 402 JAPAN ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 403 JAPAN TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 404 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 405 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 406 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 407 JAPAN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 408 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 409 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 410 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 411 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 412 JAPAN RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 413 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 414 INDIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 415 INDIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 416 INDIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 417 INDIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 418 INDIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 419 INDIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 420 INDIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 421 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 422 INDIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 423 INDIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 424 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 425 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 426 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 427 INDIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 428 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 429 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 430 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 431 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 432 INDIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 433 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 434 AUSTRALIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 435 AUSTRALIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 436 AUSTRALIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 437 AUSTRALIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 438 AUSTRALIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 439 AUSTRALIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 440 AUSTRALIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 441 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 442 AUSTRALIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 443 AUSTRALIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 444 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 445 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 446 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 447 AUSTRALIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 448 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 449 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 450 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 451 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 452 AUSTRALIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 453 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 454 SOUTH KOREA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 455 SOUTH KOREA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 456 SOUTH KOREA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 457 SOUTH KOREA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 458 SOUTH KOREA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 459 SOUTH KOREA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 460 SOUTH KOREA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 461 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 462 SOUTH KOREA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 463 SOUTH KOREA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 464 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 465 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 466 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 467 SOUTH KOREA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 468 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 469 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 470 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 471 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 472 SOUTH KOREA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 473 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 474 SINGAPORE MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 475 SINGAPORE ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 476 SINGAPORE ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 477 SINGAPORE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 478 SINGAPORE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 479 SINGAPORE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 480 SINGAPORE COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 481 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 482 SINGAPORE ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 483 SINGAPORE TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 484 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 485 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 486 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 487 SINGAPORE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 488 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 489 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 490 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 491 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 492 SINGAPORE RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 493 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 494 MALAYSIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 495 MALAYSIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 496 MALAYSIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 497 MALAYSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 498 MALAYSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 499 MALAYSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 500 MALAYSIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 501 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 502 MALAYSIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 503 MALAYSIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 504 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 505 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 506 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 507 MALAYSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 508 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 509 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 510 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 511 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 512 MALAYSIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 513 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 514 PHILIPPINES MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 515 PHILIPPINES ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 516 PHILIPPINES ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 517 PHILIPPINES APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 518 PHILIPPINES BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 519 PHILIPPINES APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 520 PHILIPPINES COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 521 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 522 PHILIPPINES ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 523 PHILIPPINES TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 524 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 525 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 526 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 527 PHILIPPINES BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 528 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 529 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 530 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 531 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 532 PHILIPPINES RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 533 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 534 INDONESIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 535 INDONESIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 536 INDONESIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 537 INDONESIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 538 INDONESIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 539 INDONESIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 540 INDONESIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 541 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 542 INDONESIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 543 INDONESIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 544 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 545 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 546 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 547 INDONESIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 548 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 549 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 550 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 551 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 552 INDONESIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 553 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 554 THAILAND MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 555 THAILAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 556 THAILAND ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 557 THAILAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 558 THAILAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 559 THAILAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 560 THAILAND COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 561 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 562 THAILAND ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 563 THAILAND TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 564 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 565 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 566 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 567 THAILAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 568 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 569 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 570 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 571 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 572 THAILAND RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 573 REST OF ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 574 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 575 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 576 SOUTH AMERICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 577 SOUTH AMERICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 578 SOUTH AMERICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 579 SOUTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 580 SOUTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 581 SOUTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 582 SOUTH AMERICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 583 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 584 SOUTH AMERICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 585 SOUTH AMERICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 586 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 587 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 588 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 589 SOUTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 590 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 591 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 592 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 593 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 594 SOUTH AMERICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 595 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 596 BRAZIL MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 597 BRAZIL ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 598 BRAZIL ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 599 BRAZIL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 600 BRAZIL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 601 BRAZIL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 602 BRAZIL COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 603 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 604 BRAZIL ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 605 BRAZIL TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 606 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 607 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 608 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 609 BRAZIL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 610 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 611 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 612 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 613 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 614 BRAZIL RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 615 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 616 ARGENTINA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 617 ARGENTINA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 618 ARGENTINA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 619 ARGENTINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 620 ARGENTINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 621 ARGENTINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 622 ARGENTINA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 623 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 624 ARGENTINA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 625 ARGENTINA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 626 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 627 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 628 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 629 ARGENTINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 630 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 631 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 632 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 633 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 634 ARGENTINA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 635 REST OF SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 636 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 637 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 638 MIDDLE EAST AND AFRICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 639 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 640 MIDDLE EAST AND AFRICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 641 MIDDLE EAST AND AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 642 MIDDLE EAST AND AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 643 MIDDLE EAST AND AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 644 MIDDLE EAST AND AFRICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 645 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 646 MIDDLE EAST AND AFRICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 647 MIDDLE EAST AND AFRICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 648 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 649 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 650 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 651 MIDDLE EAST AND AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 652 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 653 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 654 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 655 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 656 MIDDLE EAST AND AFRICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 657 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 658 SOUTH AFRICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 659 SOUTH AFRICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 660 SOUTH AFRICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 661 SOUTH AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 662 SOUTH AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 663 SOUTH AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 664 SOUTH AFRICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 665 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 666 SOUTH AFRICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 667 SOUTH AFRICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 668 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 669 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 670 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 671 SOUTH AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 672 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 673 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 674 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 675 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 676 SOUTH AFRICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 677 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 678 EGYPT MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 679 EGYPT ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 680 EGYPT ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 681 EGYPT APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 682 EGYPT BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 683 EGYPT APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 684 EGYPT COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 685 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 686 EGYPT ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 687 EGYPT TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 688 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 689 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 690 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 691 EGYPT BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 692 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 693 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 694 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 695 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 696 EGYPT RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 697 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 698 SAUDI ARABIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 699 SAUDI ARABIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 700 SAUDI ARABIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 701 SAUDI ARABIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 702 SAUDI ARABIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 703 SAUDI ARABIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 704 SAUDI ARABIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 705 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 706 SAUDI ARABIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 707 SAUDI ARABIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 708 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 709 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 710 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 711 SAUDI ARABIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 712 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 713 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 714 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 715 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 716 SAUDI ARABIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 717 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 718 U.A.E. MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 719 U.A.E. ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 720 U.A.E. ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 721 U.A.E. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 722 U.A.E. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 723 U.A.E. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)
TABLE 724 U.A.E. COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 725 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 726 U.A.E. ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 727 U.A.E. TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 728 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)
TABLE 729 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)
TABLE 730 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 731 U.A.E. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 732 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 733 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 734 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 735 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 736 U.A.E. RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
Lista de Figura
FIGURE 1 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: SEGMENTATION
FIGURE 2 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: SEGMENTATION
FIGURE 11 GROWING PREVALENCE OF COLD SORE INFECTION IS DRIVING THE GROWTH OF THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET FROM 2024 TO 2031
FIGURE 12 THE TREATMENT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET IN 2024 AND 2031
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET
FIGURE 16 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, 2023
FIGURE 17 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)
FIGURE 18 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, CAGR (2024-2031)
FIGURE 19 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, 2023
FIGURE 21 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 22 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 23 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 24 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, 2023
FIGURE 25 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, 2024-2031 (USD THOUSAND)
FIGURE 26 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, CAGR (2024-2031)
FIGURE 27 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 28 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, 2023
FIGURE 29 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, 2024-2031 (USD THOUSAND)
FIGURE 30 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, CAGR (2024-2031)
FIGURE 31 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, LIFELINE CURVE
FIGURE 32 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, 2023
FIGURE 33 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 34 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 35 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 36 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, 2023
FIGURE 37 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND)
FIGURE 38 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, CAGR (2024-2031)
FIGURE 39 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 40 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, 2023
FIGURE 41 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, 2024-2031 (USD THOUSAND)
FIGURE 42 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 43 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, LIFELINE CURVE
FIGURE 44 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, 2023
FIGURE 45 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 46 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, CAGR (2024-2031)
FIGURE 47 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 48 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 49 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 50 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 51 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 52 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: SNAPSHOT (2023)
FIGURE 53 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)
FIGURE 54 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)
FIGURE 55 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)
FIGURE 56 AISA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
